文献类型：期刊文献

英文题名：Poly(glucono-delta-lactone) based nanocarriers as novel biodegradable drug delivery platforms

作者：Xu, Xin[1];Li, Yan[1];Liu, Liping[2];Li, Yuhong[3];Ru, Guomei[3];Ding, Qiannan[3];Deng, Liping[1];Dong, Jian[1]

机构：[1]Shaoxing Univ, Sch Chem & Chem Engn, Shaoxing 312000, Zhejiang, Peoples R China;[2]Zhejiang Wanli Univ, Coll Biol & Environm Sci, Ningbo 315100, Zhejiang, Peoples R China;[3]Shaoxing Peoples Hosp, Res Ctr Med, Shaoxing 312000, Zhejiang, Peoples R China

年份：2017

卷号：526

期号：1-2

起止页码：137

外文期刊名：INTERNATIONAL JOURNAL OF PHARMACEUTICS

收录：SCI-EXPANDED(收录号：WOS:000404491400013)、、Scopus(收录号：2-s2.0-85018377149)、WOS

基金：This work was financially supported by the National Natural Science Foundation of China (No. 21674063 and 20974063) and Natural Science Foundation of Zhejiang Province (No. LY12E03001 and No. LQ16C050001).

语种：英文

外文关键词：Glucono-delta-lactone; Polymer; Drug delivery system; Nanoparticles

外文摘要：Novel biocompatible and biodegradable polymers are highly desirable and crucial in drug delivery applications in order to overcome the technical challenges and problems existing in the traditional method of poly(ethylene glycol) based drug carriers. In this study, ring-opening polymerization of a carbohydrate-derived lactone, glucono-B-lactone (GDL), generates a new highly branched polymer (PGDL) that can form stable nanoparticles through a w/o emulsification approach. The biodegradable and biocompatible particles can carry anticancer agent 5-fluorouracil (5-FU) effectively. The controlled release of 5-FU from the PGDL particles exhibits a non-Fickian mechanism without an initial burst, with an enhanced release exponent at tumoral pH. Cell viability studies by MTT assays indicate that ovarian carcinoma cells (OVCAR-3) and macrophage cells (raw 264.7) treated with PGDL (2.5 mg/ml) show no signs of toxicity in 24 h cell incubations. The PGDL particles can interact with the OVCAR-3 cell line efficiently. Therefore, the glucono-B-lactone based particles represent an effective delivery system for cancer therapy. (C) 2017 Elsevier B.V. All rights reserved.